Cargando…
Intein mediated high throughput screening for bispecific antibodies
Bispecific antibodies comprise extremely diverse architectures enabling complex modes of action, such as effector cell recruitment or conditional target modulation via dual targeting, not conveyed by monospecific antibodies. In recent years, research on bispecific therapeutics has substantially grow...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153837/ https://www.ncbi.nlm.nih.gov/pubmed/32151188 http://dx.doi.org/10.1080/19420862.2020.1731938 |
_version_ | 1783521717320155136 |
---|---|
author | Hofmann, Tim Schmidt, Johannes Ciesielski, Elke Becker, Stefan Rysiok, Thomas Schütte, Mark Toleikis, Lars Kolmar, Harald Doerner, Achim |
author_facet | Hofmann, Tim Schmidt, Johannes Ciesielski, Elke Becker, Stefan Rysiok, Thomas Schütte, Mark Toleikis, Lars Kolmar, Harald Doerner, Achim |
author_sort | Hofmann, Tim |
collection | PubMed |
description | Bispecific antibodies comprise extremely diverse architectures enabling complex modes of action, such as effector cell recruitment or conditional target modulation via dual targeting, not conveyed by monospecific antibodies. In recent years, research on bispecific therapeutics has substantially grown. However, evaluation of binding moiety combinations often leads to undesired prolonged development times. While high throughput screening for small molecules and classical antibodies has evolved into a mature discipline in the pharmaceutical industry, dual-targeting antibody screening methodologies lack the ability to fully evaluate the tremendous number of possible combinations and cover only a limited portion of the combinatorial screening space. Here, we propose a novel combinatorial screening approach for bispecific IgG-like antibodies to extenuate screening limitations in industrial scale, expanding the limiting screening space. Harnessing the ability of a protein trans-splicing reaction by the split intein Npu DnaE, antibody fragments were reconstituted within the hinge region in vitro. This method allows for fully automated, rapid one-pot antibody reconstitution, providing biological activity in several biochemical and functional assays. The technology presented here is suitable for automated functional and combinatorial high throughput screening of bispecific antibodies. |
format | Online Article Text |
id | pubmed-7153837 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-71538372020-04-20 Intein mediated high throughput screening for bispecific antibodies Hofmann, Tim Schmidt, Johannes Ciesielski, Elke Becker, Stefan Rysiok, Thomas Schütte, Mark Toleikis, Lars Kolmar, Harald Doerner, Achim MAbs Report Bispecific antibodies comprise extremely diverse architectures enabling complex modes of action, such as effector cell recruitment or conditional target modulation via dual targeting, not conveyed by monospecific antibodies. In recent years, research on bispecific therapeutics has substantially grown. However, evaluation of binding moiety combinations often leads to undesired prolonged development times. While high throughput screening for small molecules and classical antibodies has evolved into a mature discipline in the pharmaceutical industry, dual-targeting antibody screening methodologies lack the ability to fully evaluate the tremendous number of possible combinations and cover only a limited portion of the combinatorial screening space. Here, we propose a novel combinatorial screening approach for bispecific IgG-like antibodies to extenuate screening limitations in industrial scale, expanding the limiting screening space. Harnessing the ability of a protein trans-splicing reaction by the split intein Npu DnaE, antibody fragments were reconstituted within the hinge region in vitro. This method allows for fully automated, rapid one-pot antibody reconstitution, providing biological activity in several biochemical and functional assays. The technology presented here is suitable for automated functional and combinatorial high throughput screening of bispecific antibodies. Taylor & Francis 2020-03-09 /pmc/articles/PMC7153837/ /pubmed/32151188 http://dx.doi.org/10.1080/19420862.2020.1731938 Text en © 2020 Merck Healthcare KGaA. Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Report Hofmann, Tim Schmidt, Johannes Ciesielski, Elke Becker, Stefan Rysiok, Thomas Schütte, Mark Toleikis, Lars Kolmar, Harald Doerner, Achim Intein mediated high throughput screening for bispecific antibodies |
title | Intein mediated high throughput screening for bispecific antibodies |
title_full | Intein mediated high throughput screening for bispecific antibodies |
title_fullStr | Intein mediated high throughput screening for bispecific antibodies |
title_full_unstemmed | Intein mediated high throughput screening for bispecific antibodies |
title_short | Intein mediated high throughput screening for bispecific antibodies |
title_sort | intein mediated high throughput screening for bispecific antibodies |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153837/ https://www.ncbi.nlm.nih.gov/pubmed/32151188 http://dx.doi.org/10.1080/19420862.2020.1731938 |
work_keys_str_mv | AT hofmanntim inteinmediatedhighthroughputscreeningforbispecificantibodies AT schmidtjohannes inteinmediatedhighthroughputscreeningforbispecificantibodies AT ciesielskielke inteinmediatedhighthroughputscreeningforbispecificantibodies AT beckerstefan inteinmediatedhighthroughputscreeningforbispecificantibodies AT rysiokthomas inteinmediatedhighthroughputscreeningforbispecificantibodies AT schuttemark inteinmediatedhighthroughputscreeningforbispecificantibodies AT toleikislars inteinmediatedhighthroughputscreeningforbispecificantibodies AT kolmarharald inteinmediatedhighthroughputscreeningforbispecificantibodies AT doernerachim inteinmediatedhighthroughputscreeningforbispecificantibodies |